Bionano Genomics, Inc. (BNGO)

Bionano Genomics' stock price declined by 73.75% from April 10, 2025, to April 9, 2026. In Q3 2025, revenue increased by 21% to $7.4 million, with an installed base of 384 OGM systems. The company participated in the H.C. Wainwright @ Home Event on October 15, 2025. Q4 2025 revenue was $8.0 million, down 3% year-over-year, and full-year 2025 revenue was $28.5 million, down 7% year-over-year. Supply constraints for nanochannel array flowcells impacted sales in Q4 2025. Non-GAAP operating expenses were reduced by 47% in full-year 2025. The company installed 32 OGM systems in full-year 2025, bringing the total to 387. CMS increased the 2026 CLFS payment determination by 47% for the OGM hematologic code. Scientific publications and presentations highlighted OGM's performance and applications. Shareholders experienced substantial dilution, with shares outstanding increasing by 268.9%.

Bionano Genomics experiences demand seasonality, anticipating revenue growth throughout the year, with Q1 typically having lower expectations.

Bionano Genomics, Inc. is a life sciences instrumentation and genomics company focused on optical genome mapping (OGM), diagnostic services, and software. The company offers Saphyr and Stratys systems for structural variation analysis, Saphyr Chips, Bionano Prep Kits and DNA labeling kits, and an Ionic purification system. They also provide software solutions like VIA software, Bionano Access™, and Bionano Solve™ for genomic data analysis. Diagnostic testing and laboratory services are offered through Lineagen, Inc. d/b/a Bionano Laboratories, including various tests for developmental disorders and genome mapping services.

Bionano Genomics, Inc. provides its genome analysis solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions.

Bionano Genomics' brand reputation is influenced by its financial performance and the scientific validation of its technology. Market sentiment has been negatively impacted by financial results. Increasing OGM studies presented at scientific meetings and publications contribute positively to its scientific credibility. The company has an average brokerage recommendation of "Hold" from analysts.

Bionano Genomics, Inc. has a mixed ownership structure. Institutional investors hold approximately 2.23% to 3.02% of the stock, with major shareholders including Gsa Capital Partners Llp and Vanguard Group Inc. Retail investors hold approximately 95.09% of the stock, with Thomas E. Claugus owning the most shares among individual investors. Insiders own approximately 1.89% of the company's stock.